Literature DB >> 16209425

Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease.

D Galasko1, F Schmitt, R Thomas, S Jin, D Bennett.   

Abstract

Patients with Alzheimer's Disease (AD) who have reached a stage of moderate to severe dementia are capable of completing a restricted range of cognitive tests and performing a limited range of activities of daily living (ADL). As part of an initiative to develop instruments to evaluate AD, we analyzed data describing the performance of a large number of ADL and scores on cognitive and global assessment measures in a cohort of patients with AD with moderate to severe cognitive impairment, defined as a Mini-Mental State Examination score ranging from 0-15 (out of 30). From the large pool of ADL, 19 met criteria of applicability, reliability, good scaling, concordant validity, and sensitivity to detect change in performance over 6-12 months. A total score derived from these 19 ADL ratings, comprising a scale termed the Alzheimer Disease Cooperative Study ADL-sev, correlated strongly with measures of cognition and of global dementia severity. Patients with moderate to severe AD showed a decline on the ADL-sev and cognitive measures over 6 and 12 months, consistent with the progression of AD. Detailed evaluation of ADL may provide a useful index to evaluate patients with moderate to severe AD and may complement cognitive assessment, especially for characterizing change in interventional or therapeutic studies.

Entities:  

Mesh:

Year:  2005        PMID: 16209425     DOI: 10.1017/s1355617705050502

Source DB:  PubMed          Journal:  J Int Neuropsychol Soc        ISSN: 1355-6177            Impact factor:   2.892


  34 in total

Review 1.  Withdrawal of Antidementia Drugs in Older People: Who, When and How?

Authors:  Carole Parsons
Journal:  Drugs Aging       Date:  2016-08       Impact factor: 3.923

2.  Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism.

Authors:  Edward Tobinick
Journal:  Medscape J Med       Date:  2008-06-10

3.  Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.

Authors:  Martin R Farlow; Stephen Salloway; Pierre N Tariot; Jane Yardley; Margaret L Moline; Qin Wang; Elimor Brand-Schieber; Heng Zou; Timothy Hsu; Andrew Satlin
Journal:  Clin Ther       Date:  2010-07       Impact factor: 3.393

4.  A systematic review of assessment and treatment of moderate to severe Alzheimer's disease.

Authors:  Frederick A Schmitt; Christine H Wichems
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

5.  Evaluation of an 8-item Severe Impairment Battery (SIB-8) vs. the full SIB in moderate to severe Alzheimer's disease patients participating in a donepezil study.

Authors:  F A Schmitt; J Saxton; S H Ferris; J Mackell; Y Sun
Journal:  Int J Clin Pract       Date:  2013-10       Impact factor: 2.503

6.  Memantine benefits functional abilities in moderate to severe Alzheimer's disease.

Authors:  B Winblad; S Gauthier; D Aström; K Stender
Journal:  J Nutr Health Aging       Date:  2010-11       Impact factor: 4.075

7.  Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study.

Authors:  Nathan Herrmann; Jaclyn Cappell; Goran M Eryavec; Krista L Lanctôt
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

8.  [Alzheimer dementia: course and burden on caregivers : Data over 18 months from German participants of the GERAS study].

Authors:  K Hager; C Henneges; E Schneider; M Lieb; S Kraemer
Journal:  Nervenarzt       Date:  2018-04       Impact factor: 1.214

9.  Analysis of burden in caregivers of people with Alzheimer's disease using self-report and supervision hours.

Authors:  J M Haro; K Kahle-Wrobleski; G Bruno; M Belger; G Dell'Agnello; R Dodel; R W Jones; C C Reed; B Vellas; A Wimo; J M Argimon
Journal:  J Nutr Health Aging       Date:  2014-07       Impact factor: 4.075

10.  Quantitative and qualitative features of executive dysfunction in frontotemporal and Alzheimer's dementia.

Authors:  Andrew M Kiselica; Jared F Benge
Journal:  Appl Neuropsychol Adult       Date:  2019-08-19       Impact factor: 2.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.